Tag: Selective estrogen receptor antagonist ((E)-isomer of clomiphene)

  • Enclomiphene

    Selective estrogen receptor antagonist ((E)-isomer of clomiphene)

    The (E)-isomer of clomiphene; a pure ER antagonist without the estrogenic zuclomiphene component, investigated for male hypogonadism.

    Abstract

    Enclomiphene ((E)-2-[4-(2-chloro-1,2-diphenylvinyl)phenoxy]-N,N-diethylethanamine; CAS 7599-79-3; molecular formula C26H28ClNO; molecular weight 405.96) is the (E)-isomer of clomiphene, a pure ER antagonist developed by Repros Therapeutics for male hypogonadism with the trade name Androxal. The compound antagonizes hypothalamic ER, releasing negative feedback on GnRH; consequent FSH and LH elevation drives endogenous testosterone production by Leydig cells. Distinct from exogenous testosterone replacement, enclomiphene preserves spermatogenesis and testicular volume because the elevated FSH supports continued Sertoli cell function. Phase 3 trials in obese men with secondary hypogonadism demonstrated efficacy in restoring eugonadal testosterone and improving spermatogenic parameters; the FDA declined approval (twice, 2015 and 2016) citing CMC and clinical pharmacology concerns rather than efficacy. The compound has been licensed and is in development at Cosette Pharmaceuticals. Plasma half-life is approximately 30 hours, much shorter than the 30-day zuclomiphene half-life.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.